Cheryl Cohen

CIK: 0001529371

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (25.0%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

IBRX

ImmunityBio, Inc.

Director

CLDX

Celldex Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

IBRX
ImmunityBio, Inc.
Oct 2, 2026
Exercise(M)
Direct
56K shares at avg. $2.98$167K
IBRX
ImmunityBio, Inc.
Oct 2, 2026
Sale(S)
Direct
81.1K shares at avg. $10.50$851K
IBRX
ImmunityBio, Inc.
Jul 2, 2026
Exercise(M)
Direct
56K shares at avg. $2.98$167K
IBRX
ImmunityBio, Inc.
Jul 2, 2026
Sale(S)
Direct
131.2K shares at avg. $9.50$1.2M
CLDX
Celldex Therapeutics, Inc.
Jun 25, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
26K shares-
IBRX
ImmunityBio, Inc.
Jun 9, 2026
Award(A)
Stock Option (right to buy)
Direct
65.6K shares-
IBRX
ImmunityBio, Inc.
Jun 18, 2025
Award(A)
Stock Option (right to buy)
Direct
162.8K shares-
CLDX
Celldex Therapeutics, Inc.
Jun 5, 2025
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
16.5K shares-

		Type	Shares	Price		Ownership
Oct 2, 2026	IBRX ImmunityBio, Inc.	Exercise(M)	55,979	$2.98	$166,817	Direct
Oct 2, 2026	IBRX ImmunityBio, Inc.	Sale(S)	81,056	$10.50	$851,088	Direct
Jul 2, 2026	IBRX ImmunityBio, Inc.	Exercise(M)	55,979	$2.98	$166,817	Direct
Jul 2, 2026	IBRX ImmunityBio, Inc.	Sale(S)	131,210	$9.50	$1,246,941	Direct
Jun 25, 2026	CLDX Celldex Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	26,000	-	-	Direct
Jun 9, 2026	IBRX ImmunityBio, Inc.	Award(A) Stock Option (right to buy)	65,600	-	-	Direct
Jun 18, 2025	IBRX ImmunityBio, Inc.	Award(A) Stock Option (right to buy)	162,786	-	-	Direct
Jun 5, 2025	CLDX Celldex Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	16,500	-	-	Direct

1-8 of 8 transactions

About Cohen Cheryl

Cohen Cheryl (SEC CIK 0001529371) files insider reports with the SEC as Director of ImmunityBio, Inc. (IBRX) and Director of Celldex Therapeutics, Inc. (CLDX).

Signal8 holds 6 ownership filings by Cohen Cheryl, all Form 4s, filed between Jun 9, 2025 and Oct 6, 2026. Those filings report 8 transactions, from Jun 5, 2025 to Oct 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cohen Cheryl's filings is in SAN DIEGO, CA.

Recent filings by Cohen Cheryl

Oct 2, 2026: Option exercise of IBRX shares (Form 4, code M).
Oct 2, 2026: Open-market sale of IBRX shares (Form 4, code S).
Jul 2, 2026: Option exercise of IBRX shares (Form 4, code M).
Jul 2, 2026: Open-market sale of IBRX shares (Form 4, code S).
Jun 25, 2026: Grant or award of CLDX derivative securities (Form 4, code A).

Other insiders filing for ImmunityBio, Inc. (IBRX)

Simon Barry J., Director
Selecky Christobel, Director
BLASZYK MICHAEL D, Director
Wendel Bruce, Director
MAXWELL LINDA, Director
Clark Wesley, Director

How to read Form 4 transaction codes